1st step: Important as the invention of the wheel
Historically, most vaccines, such as those against measles, polio, and yellow fever, were made from killed or weakened whole viruses. This is the old story about milkmaids exposed to the mild cowpox disease who avoided much more deadly smallpox.
2nd step: Vaccines move up to horse and buggy speeds
In more recent years, vaccines based on viral parts rather than whole viruses have been developed. These types of vaccines, such as those for hepatitis B and the human papillomavirus, use only genetic pieces so our body learns to recognize and then build our own antibodies to block the virus.
3rd step: Finding “Interstate highway” levels of vaccine performance
Other types of vaccines, such as the first versions against the Ebola virus, use a harmless virus as a transport carrying only a part of the disease-causing virus into the body. Again this teaches our cells to produce specific proteins as part of our immune response against the illness.
Next: Related therapies take flight
Each of these older types of vaccines, however, have manufacturing requirements that make them difficult to produce quickly for a disease outbreak, hard to develop a personal therapy just for your body, or protect against an entirely new pandemic virus.
New answers around 2010
These next steps use new techniques from the mid-to-late 2000s that used to create vaccines against the Zika virus. Then in the 2010s, scientists began to study the coronavirus responsible for MERS (Middle East Respiratory Syndrome) and used these same techniques to develop other specific new vaccines. Another major disease pandemic was avoided. The solution they found came from advances in nanotechnology: the development of fatty droplets (lipid nanoparticles) that wrapped the mRNA like a bubble. This allowed entry of fragile parts into the cells. Once inside the cell, the mRNA message could be translated into proteins, and the immune system would then be primed to recognize the foreign virus.
The first vaccines using these fatty envelopes were developed against the deadly Ebola virus, but since that virus is only found in a limited number of African countries, it had no commercial development for a long time in the U.S.